Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Sapience Therapeutics

  • Barry Kappel, Sapience Therapeutics

Sapience Therapeutics is a privately held company focused on discovering and developing peptide-based therapeutics to previously ‘undruggable’ targets for major unmet medical needs, particularly high mortality cancers. Sapience identifies promising targets through a deep understanding of the transcriptional regulation of oncogenic or immune-modulatory proteins. Our targets may be non-traditional in drug discovery as they do not demonstrate enzymatic activities or act as ligand-binding receptors. Sapience has multiple approaches to generate initial hits, which are then optimized to therapeutic candidates based on decades of experience working with peptide and protein therapeutics. Sapience is looking to raise a series B financing in the first half of 2019.

  • Date:Tuesday, February 12
  • Time:1:15 PM - 1:30 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23426
  • Goal for Presentation:Gain Investment Community Exposure
  • Company Website:https://www.sapiencetherapeutics.com/
  • Company HQ City:Harrison
  • Company HQ State:New York
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:22.5 million
  • Year Founded:2015
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:ST101
  • Development Phase of Primary Product:Pre-Clinical
Speakers
Barry Kappel
Sapience Therapeutics
Back